Pharmacologic modulators of fracture healing: The role of cyclooxygenase inhibition

Journal of Musculoskeletal Neuronal Interactions

Volumn 3, Issue 4, 2003, Pages 308-312

  Puzas, J Edward ^a   O'Keefe, R J ^a   Schwarz, E M ^a   Zhang, X ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Biomechanics; Collagenous tissue; Mechanical influences; Muscle; Plastic surgery; Sports medicine

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; STEROID;

ARTICLE; BONE REMODELING; CELL DIFFERENTIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; ENZYME INHIBITION; FRACTURE HEALING; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; OVARIECTOMY; RHEUMATOID ARTHRITIS;

EID: 1642431911     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Ferguson C, Alpern E, Miclau T, Helms JA. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 1999; 87:57-66.
2. Le AX, Miclau T, Hu D, Helms JA. Molecular aspects of healing in stabilized and non-stabilized fractures. J Orthop Res 2001; 19:78-84.
3. Einhorn TA. The cell and molecular biology of fracture healing. Clin Orthop 1998; (Suppl.355):S7-S21.
4. Buckwalter JA, Einhorn TA, Bolander ME, Crue RL. Healing of the musculoskeletal tissues. In: Rockwood CA Jr, Green DP (eds) Fractures in Adults. Lippincott-Raven, Philadelphia; 2001:261.
5. Cruess RL, Dumont J. Fracture healing. Can J Surg 1975; 18:403-413.
6. Namkung-Matthai H, Appleyard R, Jansen J, Lin JH, Maastricht S, Swain M, Mason RS, Murrell GA, Diwan AD, Diamond T. Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. Bone 2001; 28:80-86.
7. Waters RV, Gamradt SC, Asnis P, Vickery BH, Avnur Z, Hill E, Bostrom M. Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model. Acta Orthop Scand 2000; 71:316-321.
8. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Bio Chem 1991; 266:12866-12872.
9. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266:23261-23267.
10. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992; 89:4888-4892.
11. Sirois J, Simmons DL, Richards JS. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat prevulatory follicles. Induction in vivo and in vitro. J Bio Chem 1992; 267:11586-11592.
12. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors, J Rheumatol 1997; 24:20-24.
13. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41:1591-1602.
14. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol 1989; 163:3-8.
15. Hirschowitz BI. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract, Gastroenterologist. 1994; 2:207-223.
16. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci USA 1994; 91:3228-3232.
17. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95:1681-1690.
18. O'Banion MK. COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. Expert Opin Investig Drugs 1999; 8:1521-1536.
19. Dubois RN. Cyclooxygenase-a target for colon cancer prevention. Aliment Pharmacol Ther 2000; 1(Suppl.4):64-67.
20. Geng Y, Blanco FJ, Cornelisson M, Lotz M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J Immunol 1995; 155:796-801.
21. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions,. J Rheumatol 1997; 24:15-19.
22. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83:483-492.
23. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83:473-482.
24. Dinchuk JE, Car B, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378:406-409.
25. Facchini R, Selva G, Peretti G. Tolerability of nimesulide and ketoprofen in paediatric patients with traumatic or surgical fractures. Drugs 1993; 46:238-241.
26. Pierce MC, Fuchs S. Evaluation of ketorolac in children with forearm fractures. Acad Emergency Med 1997; 4:22-26.
27. Egbert AM. Post-operative pain management in the frail elderly. Clin Geriatric Med 1996; 12:583-599.
28. Cramer GW, Galer BS, Mendelson MA, Thompson GD. A drug use evaluation of selected opioid and nonopioid analgesics in the nursing facility setting. J Amer Geriatr Soc 2000; 48:398-404.
29. Fredericson M, Bergman AG, Hoffman KL, Dillingham MS. Tibial stress reaction in runners. Correlation of clinical symptoms and scintigraphy with a new,magnetic resonance imaging grading system. Amer J Sports Med 1995; 23:472-481.
30. Massart P, Bezes H. Comparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents. Br J Clin Pharmacol 1986; 22:161S-165S.
31. Reuben SS, Connelly NR, Steinberg R. Ketorolac as an adjunct to patient-controlled morphine in postoperative spine surgery patients. Reg Anesth 1997; 22:343-346.
32. Altman RD, Latta LL, Keer R, Renfree K, Hornicek FJ, Banovac K. Effect of non-steroidal anti-inflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma 1995; 9:392-400.
33. Ho ML, Chang JK, Wang GJ. Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits. Pharmacology 1998; 57:148-159.
34. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Non-union of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg 2000; 82B:655-658.
35. Dimar JRN II, Ante WA, Zhang YP, Glassman SD. The effects of non-steroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Spine 1996; 21:1870-1876.
36. Martin GJJ, Boden SD, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion. Spine 1999; 24:2188-2193.
37. Deguchi M, Rapoff AJ, Zdeblick TA. Posterolateral fusion for isthmic spondylolisthesis in adults: analysis of fusion rate and clinical results. J Spinal Disord 1998; 11:459-464.
38. Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of post-operative non-steroidal anti-inflammatory drug administration on spinal fusion. Spine 1998; 23:834-838.
39. Kjaersgaard-Andersen P, Hougaard K, Linde F, Christiansen SE, Jensen J. Heterotopic bone formation after total hip arthroplasty in patients with primary or secondary coxarthrosis. Orthopedics 1990; 13:1211-1217.
40. Moore KD, Goss K, Anglen JO. Indomethacin versus radiation therapy for prophylaxis against heterotopic ossification in acetabular fractures: a randomised, prospective study. J Bone Joint Surg Br 1998; 80B:259-263.
41. Beingessner DM, Patterson SD, King GJ. Early excision of heterotopic bone in the forearm. J Hand Surg 2000 ; 25:483-488.
42. Norrdin RW, Shih MS. Systemic effects of prostaglandin E2 on vertebral trabecular remodeling in beagles used in a healing study. Calcif Tissue Int 1988; 42:363-368.
43. Keller J, Klamer A, Bak B, Suder P. Effect of local prostaglandin E2 on fracture callus in rabbits. Acta Orthop Scand 1993; 64:59-63.
44. Suponitzky I, Weinreb M. Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J Endocrinol 1998; 156:51-57.
45. Kokubu T, Matsui N, Fujioka H, Tsunoda M, Mizuno K. Low intensity pulsed ultrasound exposure increases prostaglandin E2 production via the induction of cyclooxygenase-2 mRNA in mouse osteoblasts. Biochem Biophys Res Com 1999; 256:284-287.
46. Dekel S, Lenthall G, Francis MJ. Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits. J Bone Joint Surg Br 1981; 63-B:185-189.
47. Gerstenfeld L, Thiede M, Serbert K, Mielke C, Tewari S, Svagar B, Cullinane D, Einhorn T. Differential inhibition of fracture healing by non-specific and cyclooxygenase-2 (COX-2 ) specific non-steroidal anti-inflammatory drugs. Transactions ORS 2002; paper no: 0239.
48. Weinreb M, Suponitzky I, Keila S. Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone 1997; 20:521-526.
49. Weinreb M, Grosskopf A, Shir N. The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype. Am J Physiol 1999; 276:E376-383.
50. Kaneki H, Takasugi I, Fujieda M, Kiriu M, Mizuochi S, Ide H. Prostaglandin E2 stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts. J Cell Biochem 1999; 73:36-48.
51. Tang LY, Kimmel DB, Jee WS, Yee JA. Functional characterization of prostaglandin E2 inducible osteogenic colony forming units in cultures of cells isolated from the neonatal rat calvarium. J Cell Physiol 1996; 166:76-83.
52. Nagata T, K. Kaho K, Nishikawa S, Shinohara H, Wakano Y, Ishida H. Effect of prostaglandin E2 on mineralization of bone nodules formed by fetal rat calvarial cells. Calcif Tissue Int 1994; 55:451-457.
53. Flanagan AM, Chambers TJ. Stimulation of bone nodule formation in vitro by prostaglandins E1 and E2. Endocrinol 1992; 130:443-448.
54. Suponitzky I, Weinreb M. Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J Endocrinol 1998; 156:51-57.
55. Keila S, Kelner A, Weinreb M. Systemic prostaglandin E2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro. J Endocrinol 2001; 168:131-139.
56. Scutt A, Zeschnigk M, Bertram P. PGE2 induces the transition from non-adherent to adherent bone marrow mesenchymal precursor cells via a cAMP/EP2-mediated mechanism. Prostaglandins 1995; 49:383-395.
57. Paralkar VM, Grasser WA, Mansolf AL, Baumann AP, Owen TA, Smock SL, Martinovic S, Borovecki F, Vukicevic S, Ke HZ, Thompson DD. Regulation of BMP-7 expression by retinoic acid and prostaglandin E(2). J Cell Physiol 2002; 190:207-217.